FY2026 EPS Estimates for argenx SE Boosted by Leerink Partnrs (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX) – Research analysts at Leerink Partnrs upped their FY2026 earnings estimates for argenx in a report issued on Saturday, June 22nd. Leerink Partnrs analyst T. Smith now expects that the company will post earnings of $6.30 per share for the year, up from their previous forecast of $5.86. The consensus estimate for argenx’s current full-year earnings is ($2.89) per share.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The firm had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. During the same period in the previous year, the firm earned ($0.52) earnings per share.

A number of other analysts have also issued reports on the stock. Robert W. Baird lowered their target price on shares of argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. HC Wainwright reissued a “buy” rating and set a $448.00 target price on shares of argenx in a research note on Monday. Wedbush reissued an “outperform” rating and set a $519.00 target price on shares of argenx in a research note on Wednesday. Scotiabank boosted their target price on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a research note on Tuesday, March 26th. Finally, Wells Fargo & Company boosted their target price on shares of argenx from $478.00 to $542.00 and gave the company an “overweight” rating in a research note on Monday. Five research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $525.42.

argenx Trading Down 1.3 %

Shares of ARGX opened at $445.88 on Tuesday. The firm has a market capitalization of $26.50 billion, a P/E ratio of -78.78 and a beta of 0.65. argenx has a 12-month low of $327.73 and a 12-month high of $550.76. The firm has a fifty day moving average price of $379.85 and a 200-day moving average price of $386.89.

Hedge Funds Weigh In On argenx

A number of large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in argenx by 49.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after purchasing an additional 1,830,651 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in argenx by 12.2% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock worth $1,207,666,000 after purchasing an additional 346,178 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of argenx by 24.8% during the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock valued at $872,690,000 after acquiring an additional 439,889 shares in the last quarter. Capital World Investors increased its holdings in shares of argenx by 37.0% during the fourth quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after acquiring an additional 530,181 shares in the last quarter. Finally, Avoro Capital Advisors LLC increased its holdings in shares of argenx by 0.3% during the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock valued at $487,609,000 after acquiring an additional 3,900 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.